We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
+34.19%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$180B
AUM Growth
+$34.5B
Cap. Flow
+$124M
Cap. Flow %
0.07%
Top 10 Hldgs %
43.41%
Holding
443
New
192
Increased
135
Reduced
77
Closed
14

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$1.73B
2
ONC
BeOne Medicines Ltd
ONC
+$774M
3
ILMN icon
Illumina
ILMN
+$691M
4
DXCM icon
DexCom
DXCM
+$438M
5
NFLX icon
Netflix
NFLX
+$360M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 37.71%
2 Technology 16.18%
3 Healthcare 15.43%
4 Communication Services 14.41%
5 Financials 5.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RARE icon
351
Ultragenyx Pharmaceutical
RARE
$2.55B
$15K ﹤0.01%
+106
New +$12.6K
SLAB icon
352
Silicon Laboratories
SLAB
$7.23B
$15K ﹤0.01%
+119
New +$13.4K
SWK icon
353
Stanley Black & Decker
SWK
$15.7B
$15K ﹤0.01%
+82
New +$14.5K
VIAV icon
354
Viavi Solutions
VIAV
$9.66B
$15K ﹤0.01%
+996
New +$13.2K
SILK
355
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$15K ﹤0.01%
+233
New +$14.5K
BRC icon
356
Brady Corp
BRC
$4.57B
$14K ﹤0.01%
+256
New +$11.3K
HUBB icon
357
Hubbell
HUBB
$27.2B
$14K ﹤0.01%
+92
New +$14.1K
JNJ icon
358
Johnson & Johnson
JNJ
$625B
$14K ﹤0.01%
+88
New +$13K
SHAK icon
359
Shake Shack
SHAK
$2.87B
$14K ﹤0.01%
+163
New +$12.7K
TDY icon
360
Teledyne Technologies
TDY
$32B
$14K ﹤0.01%
+35
New +$12.6K
KYNB
361
Kyntra Bio
KYNB
$29.4M
$13K ﹤0.01%
+14
New +$14.7K
PACB icon
362
Pacific Biosciences
PACB
$370M
$13K ﹤0.01%
+508
New +$8.63K
SYK icon
363
Stryker
SYK
$130B
$13K ﹤0.01%
+55
New +$12.5K
ACN icon
364
Accenture
ACN
$108B
$12K ﹤0.01%
+47
New +$11.3K
EXPD icon
365
Expeditors International
EXPD
$23.2B
$12K ﹤0.01%
+130
New +$11.8K
FOLD
366
DELISTED
Amicus Therapeutics
FOLD
$12K ﹤0.01%
+535
New +$10.9K
HRL icon
367
Hormel Foods
HRL
$13.8B
$12K ﹤0.01%
+247
New +$12.1K
JJSF icon
368
J&J Snack Foods
JJSF
$1.71B
$12K ﹤0.01%
+79
New +$11.5K
JKHY icon
369
Jack Henry & Associates
JKHY
$11.1B
$12K ﹤0.01%
+73
New +$11.6K
LCII icon
370
LCI Industries
LCII
$2.65B
$12K ﹤0.01%
+89
New +$10.9K
LOW icon
371
Lowe's Companies
LOW
$125B
$12K ﹤0.01%
+72
New +$11.7K
AXNX
372
DELISTED
Axonics, Inc. Common Stock
AXNX
$12K ﹤0.01%
+249
New +$11.7K
TWOU
373
DELISTED
2U Inc
TWOU
$12K ﹤0.01%
+10
New +$10.7K
AFIB
374
DELISTED
Acutus Medical Inc
AFIB
$12K ﹤0.01%
+418
New +$11.3K
NEWR
375
DELISTED
New Relic, Inc.
NEWR
$12K ﹤0.01%
+184
New +$11.3K

Similar funds

Baillie Gifford & Co's Q4 2020 Portfolio in Review

As of Q4 2020, Baillie Gifford & Co held 443 positions worth $180B, up 24% from $145B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Baillie Gifford & Co's Q4 2020 filing shows 192 new, 135 increased, 77 reduced and 14 closed positions. Its largest new stake was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M. The largest sale was Tesla, an estimated $3.79B.

By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, up from 37% a quarter earlier, followed by Technology and Healthcare.

  • Baillie Gifford & Co's largest Q4 2020 buy was Kingsoft Cloud Holdings: 7,346,496 shares worth $320M.
  • Baillie Gifford & Co added most to Moderna in Q4 2020, an estimated $1.73B increase.
  • Baillie Gifford & Co's biggest Q4 2020 reduction was Tesla, cutting an estimated $3.79B.
  • Baillie Gifford & Co fully exited TD Ameritrade Holding Corp in Q4 2020, selling an estimated $264M.
  • Baillie Gifford & Co's ten largest holdings make up 43% of its $180B portfolio in Q4 2020.
  • Baillie Gifford & Co opened 192 new positions and closed 14 in Q4 2020.
  • Baillie Gifford & Co's portfolio value rose 24% quarter-over-quarter to $180B.

Based on Baillie Gifford & Co's 13F filing for Q4 2020, filed 10 Feb 2021.